Menu
210322_Toraymyxin-EAA-homepage_653x337px

Sepsis and septic shock

TORAYMYXIN®

State-of-the-art therapy for patients with endotoxic septic shock

Septic shock is associated with an unacceptable high mortality and a significant economic burden to the sanitary system. Endotoxin is the most potent trigger of the septic cascade and during the progress of sepsis, endotoxin levels can increase up to 1000 fold, even when cultures result negative for Gram-negative bacteria.

Toraymyxin®  Polymyxin B hemoperfusion therapy – from Toray Medical Ltd. (Japan), is the state-of-the-art therapy for endotoxin removal in septic shock patients. More than 200,000 patients have been treated with this innovative therapy and more than 400 peer-reviewed articles have been published, demonstrating the beneficial effects on hemodynamics, organ function and mortality. Toraymyxin® is now available in two versions: PMX-20R device for patients with adult body volume and PMX-0.5R device for patients with reduced body volume.

EAA™Endotoxin Activity Assay – is the only FDA approved diagnostic assay to detect endotoxin activity in human whole blood. The EAA™ diagnostic test is performed in less than 30 minutes. EAA™ is the diagnostic assay to identify patients with endotoxic septic shock.

chronic-kidney-disease-653x337

Chronic kidney disease

TORAY PMMA FILTRYZER

A personalized therapy based on the individual needs of each patient

Hemofeel_Web_EN_653x337px

Acute kidney injury

HEMOFEELTM

HEMOFEELTM is a new membrane for continuous renal support made of polymethylmethacrylate, a highly hemo- and biocompatible material designed by TORAY – a global leader in advanced materials.

Focus on

210406_Focus-On_ITACTA-On-Demand_653x337px

ITACTA WEBINAR – ON-DEMAND

The webinar entitled “Endotoxemia and role of Polymyxin B hemoperfusion in the cardiovascular intensive care unit” held in collaboration with ITACTA (Italian Association of Cardiothoracic Anaesthesiologists)is now available ON-DEMAND. This webinar aims to describe and discuss the pathogenic action of endotoxemia in various clinical contests of patients hospitalized in a cardiovascular intensive care unit and the role of Polymyxin B hemoperfusion as possible therapeutic option in adult and pediatric patients.

210406_Focus-On_ITACTA_653x337px

ITACTA WEBINAR

On April 15th, 2021, at 5pm (CEST), in collaboration with ITACTA (Italian Association of Cardiothoracic Anaesthesiologists) Estor is supporting an Italian language webinar entitled: “Endotoxemia and role of Polymyxin B hemoperfusion in the cardiovascular intensive care unit”.
This webinar aims to describe and discuss the pathogenic action of endotoxemia in various clinical contests of patients hospitalized in a cardiovascular intensive care unit and the role of Polymyxin B hemoperfusion as possible therapeutic option in adult and pediatric patients.

210401_Focus-On_Hemofeel_653x337px

Reduction of complement activation and renal dysfunction with PMMA-based CVVH treatment in sepsis-induced AKI

New relevant findings on the role of polymethylmethacrylate (PMMA)-based CVVH in an animal model of sepsis-induced AKI have been published in Frontiers of Immunology. The results show that PMMA-based CVVH significantly reduces tissue and systemic complement activation limiting renal damage and fibrosis highlighting the potential role of PMMA membrane as a therapeutic strategy in patients with septic acute kidney injury (AKI).